RxDoctor Payments Data

Kristine Diehl, MD

Family Medicine · Wilmington, DENPI 1245213933

Payments from drug & device makers

$409in general payments, 2019–2025

Across 25 payments — averaging $16.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$79
  • Sanofi-aventis U.S. LLC$57
  • Pfizer$52
  • AstraZeneca$51
  • Endo Pharmaceuticals Inc.$23
  • Novo Nordisk$19
  • plus $129 from 8 others

What the payments were for

  • Food & beverage$409100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$409 in reported general payments places this provider in the 55th percentile of 352 family medicine providers in Delaware.

See all family medicine providers in Delaware

Medicare billing

Part B allowed, 2024
$362,373
Medicare patients
540
Services billed
4,303

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide59$90,945
EliquisApixaban43$47,758
JardianceEmpagliflozin40$42,281
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$30,461
Janumet XrSitagliptin Phos/Metformin Hcl11$16,790
XareltoRivaroxaban15$16,549
Breo ElliptaFluticasone/Vilanterol26$14,593
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr21$12,976
Atorvastatin Calcium688$8,198
Valsartan221$5,974
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$3,762
Rosuvastatin Calcium202$3,682
Duloxetine Hcl54$3,470
Levothyroxine Sodium306$3,082
Bupropion XlBupropion Hcl64$2,882

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$19$90,94559 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$79$58,03073 claims
PfizerEliquis$52$47,75843 claims
MerckJanumet Xr$19$16,79011 claims
Johnson & JohnsonXarelto$13$16,54915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 352 family medicine providers in Delaware.

Other family medicine in Wilmington

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →